Swiss drugmaker Roche has announced plans to initiate a new global Phase 3 clinical trial for Elevidys. This move is a strategic effort to reverse fortunes after the Duchenne muscular dystrophy gene therapy faced a rejection from European regulators last year.
Context and Setbacks: Roche holds the commercialization rights for Elevidys outside the United States. Despite being approved in nine countries, the therapy endured a turbulent 2025:
-
EMA Rejection: The European Medicines Agency (EMA) issued a negative opinion last year, noting that clinical testing failed to demonstrate a meaningful benefit on motor function.
-
Safety Incidents: In the U.S., the treatment was briefly removed from the market and subsequently restricted to specific patient groups following its link to two patient deaths.
-
Financial Pressure: Declining sales prompted the original developer, Sarepta Therapeutics, to downsize its workforce and significantly lower its financial outlook for the therapy.
New Trial Specifications: Following discussions with the EMA, Roche has designed a new study intended to address remaining scientific doubts:
-
Participants: Approximately 100 “early ambulatory” Duchenne patients.
-
Methodology: A randomized, placebo-controlled study conducted over 72 weeks.
-
Primary Objective: Measuring the change in “time to rise” from the floor—a critical predictor of future disease progression.
Expectations and Timeline: Roche’s Chief Medical Officer, Levi Garraway, expressed confidence in the therapy’s durable efficacy, citing the real-world experience of treating over 1,000 ambulatory boys worldwide. Nevertheless, market analysts anticipate a lengthy road ahead; the study is expected to take roughly 18 months to enroll, with results not anticipated until 2028.